P336 Behavioural treatment options for psychological comorbidities in patients with inflammatory bowel disease: a systematic literature review
L. Keefer1, R. Cheung*2, M. Bernauer3, D. Patel2, M. Dubinsky1
1Icahn School of Medicine at Mount Sinai, New York City, USA, 2Pfizer Inc., New York City, USA, 3Pharmerit International, Bethesda, USA
Many patients with inflammatory bowel disease (IBD) have psychological comorbidities, such as anxiety and depression. We report results from a systematic literature review (SLR) conducted to explore the burden, behavioural treatment options, and unmet needs associated with psychological comorbidities in patients with IBD.
MEDLINE® and Embase® were searched (via ProQuest®) for articles and conference abstracts (published January 2003–August 2018) on psychological comorbidities in IBD (ie, anxiety and depression). Studies in adult and adolescent populations were included. Outcomes including epidemiology, behavioural treatments, and unmet needs were reviewed.
Of 1,551 publications identified, 69 on clinical burden/unmet needs were included (31 articles; 38 conference abstracts). In patients with IBD, prevalence of depression ranged from 2.2%1 to 62.3%2 and anxiety ranged from 7.6%3 to 41.8%.4 Cognitive behavioural therapy (CBT), which is effective in the treatment of anxiety and depression,5 reduces the rate of comorbid anxiety and depression when present in adolescents and adults with IBD (Figure).6–9 Schedule for Affective Disorders and Schizophrenia for School-Age Children–Present and Lifetime Version scores significantly improved after CBT (baseline 5.64; endpoint assessment 1.09,
This SLR shows behavioural interventions, such as CBT and group therapy, were effective at reducing anxiety and depression in patients with IBD. However, there are gaps in patient care and access to these treatments where healthcare professionals could intervene to improve outcomes in this patient population.